HomeARCT • NASDAQ
Arcturus Therapeutics Holdings Inc
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 29.38M | -22.70% |
Operating expense | 11.32M | -23.81% |
Net income | -14.08M | 47.51% |
Net profit margin | -47.91 | 32.09% |
Earnings per share | -0.52 | 48.00% |
EBITDA | -16.03M | 45.69% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 216.95M | -24.77% |
Total assets | 331.79M | -20.79% |
Total liabilities | 98.03M | -36.71% |
Total equity | 233.76M | — |
Shares outstanding | 27.12M | — |
Price to book | 1.40 | — |
Return on assets | -12.45% | — |
Return on capital | -15.41% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -14.08M | 47.51% |
Cash from operations | -35.14M | -532.32% |
Cash from investing | -137.00K | 42.92% |
Cash from financing | 15.20M | 594.47% |
Net change in cash | -20.08M | -456.39% |
Free cash flow | -12.28M | -137.89% |
Previous close
$12.03
Day range
$11.70 - $12.50
Year range
$8.04 - $44.99
Market cap
323.28M USD
Avg Volume
409.05K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Founded
2013
Website
Employees
175
